The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Weight Gain and Metabolic Changes During Treatment with Antipsychotics and Antidepressants
Open accessAbstract
Weight gain and metabolic disturbances are common side effects during psychopharmacological treatment with specific antipsychotics and antidepressants. The antipsychotics clozapine and olanzapine, and antidepressants tricyclics and mirtazapine have a high risk of inducing weight gain. Recently discovered pathophysiological mechanisms include antihistaminergic effects, activation of hypothalamic adenosine monophosphate-activated protein kinase (AMPK), modulation of hormonal signaling of ghrelin and leptin, changes in the production of cytokines such as tumor necrosis factor-alpha (TNF)-alpha and adipokines such as adiponektin, and the impact of genes, in particular the melanocortin 4 receptor (MC4R), serotonin 2C receptor (HTR2C), leptin, neuropeptide Y (NPY) and cannabinoid receptor 1 (CNR1) genes. Metabolic changes associated with weight gain include disturbances of glucose and lipid metabolism. Clozapine and olanzapine may, in addition to mechanisms resulting from weight gain, impair glucose metabolism by blockade of the muscarinic M3 receptor (M3R). Antidepressants associated with weight gain appear to have fewer unfavourable effects on glucose and lipid metabolism than the second-generation antipsychotics clozapine and olanzapine. To assess the risk of weight gain and its consequences for the patient's health, assessing body weight changes and metabolic monitoring in the first week of treatment as well as in long-term treatment is recommended.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, cytokine changes might also be the consequence of a psychiatric disorder, for example they can be a consequence of treatment with psychopharmacological agents or of weight changes that appear during acute episodes of the disorder or during recovery (117).”
From Cytokine Research in Depression: Principles, Challenges, and Open Questions (2019) · cites this paper as [117]
In the citing paper
“Also, psychopharmacological medication, specifically those agents which lead to weight gain, have been reported to activate cytokine production (117, 194).”
From Cytokine Research in Depression: Principles, Challenges, and Open Questions (2019) · cites this paper as [117]
In the citing paper
“Among antipsychotics, it has been shown that those with the highest risk of weight gain, for example clozapine and olanzapine (117), lead to a significant increase in pro-inflammatory cytokine levels in the blood (194).”
From Cytokine Research in Depression: Principles, Challenges, and Open Questions (2019) · cites this paper as [117]
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus
Minokoshi, Y., Alquier, T., Furukawa, N., Kim, Y.-B., Lee, A., Xue, B., Mu, J., Foufelle, F., Ferré, P., Birnbaum, M. J., et al. (2004) · Nature · doi:10.1038/nature02440 · Cited by 1,637
McEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., Meltzer, H. Y., Hsiao, J., Scott Stroup, T., & Lieberman, J. A. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.014 · Cited by 1,140
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951
Kroeze, W. K., Hufeisen, S. J., Popadak, B. A., Renock, S. M., Steinberg, S., Ernsberger, P., Jayathilake, K., Meltzer, H. Y., & Roth, B. L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300027 · Cited by 801
Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 675
Metabolic syndrome in people with schizophrenia: a review
DE HERT, M., SCHREURS, V., VANCAMPFORT, D., & VAN WINKEL, R. (2009) · World Psychiatry · doi:10.1002/j.2051-5545.2009.tb00199.x · Cited by 634
The Role of Leptin in Human Obesity and Disease: A Review of Current Evidence
Mantzoros, C. S. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-8-199904200-00014 · Cited by 584
Lithium toxicity profi le: a systematic review and meta-analysis
McKnight, R. F., Budge, K., Ba, S., Goodwin, G. M., Geddes, J. R., & Adida, M. (2012) · Cited by 544
Cited by
Cytokine Research in Depression: Principles, Challenges, and Open Questions
Himmerich, H., Patsalos, O., Lichtblau, N., Ibrahim, M. A. A., & Dalton, B. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00030 · Cited by 313
Self-citationOn inflammatory hypothesis of depression: what is the role of IL-6 in the middle of the chaos?
Roohi, E., Jaafari, N., & Hashemian, F. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02100-7 · Cited by 225
“, clozapine and olanzapine), cause significant increase in the blood levels of proinflammatory cytokine [101].”
BackgroundGafoor, R., Booth, H. P., & Gulliford, M. C. (2018) · BMJ · doi:10.1136/bmj.k1951 · Cited by 205
Obesity II: Establishing causal links between chemical exposures and obesity
Heindel, J. J., Howard, S., Agay-Shay, K., Arrebola, J. P., Audouze, K., Babin, P. J., Barouki, R., Bansal, A., Blanc, E., Cave, M. C., et al. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115015 · Cited by 195
Himmerich, H., Kan, C., Au, K., & Treasure, J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107667 · Cited by 137
Self-citation
Metadata
- Authors
- Himmerich, H., Minkwitz, J., & Kirkby, K.
- Affiliations
- Leipzig University (DE)
- Venue
- Endocrine, Metabolic & Immune Disorders-Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2015-12-08
- Volume
- 15
- Issue
- 4
- Pages
- 252-260
- ISSN
- 1871-5303 (ISSN-L)
- OpenAlex
- W2099189795
- Cited by
- 122
- References
- 89
- Citations by year
- 2026: 10 · 2025: 5 · 2024: 12 · 2023: 16 · 2022: 13 · 2021: 12 · 2020: 11 · 2019: 15 · 2018: 11 · 2017: 11 · 2016: 4 · 2015: 2
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- Locations
- Endocrine Metabolic & Immune Disorders - Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- eCite Digital Repository (University of Tasmania) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- antipsychotic-induced weight gain, antidepressant-induced weight gain, clozapine, olanzapine, tricyclic antidepressants, mirtazapine, metabolic side effects, glucose metabolism, lipid metabolism, AMPK, ghrelin, leptin, adiponectin, TNF-α, neuropeptide Y, melanocortin-4 receptor, 5-HT2C receptor, CB1 receptor, M3 muscarinic receptor, metabolic monitoring
- MeSH terms
- Animals, Antidepressive Agents, Humans, Hyperlipidemias, Polymorphism, Genetic, Antipsychotic Agents, Weight Gain, Drug Monitoring, Glucose Intolerance, Genetic Predisposition to Disease, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Weight Gain and Metabolic Changes During Treatment with Antipsychotics and Antidepressants. https://app.cochat.ai/papers/10.2174/1871530315666150623092031
- The paper
- Himmerich, H., Minkwitz, J., & Kirkby, K. (2015). Weight Gain and Metabolic Changes During Treatment with Antipsychotics and Antidepressants. Endocrine, Metabolic & Immune Disorders-Drug Targets. https://doi.org/10.2174/1871530315666150623092031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.